Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director · Co-Chief Executive Officer | February 11, 2026 | February 13, 2026 |
| Intec Pharma Ltd.NTEC · Entity 146542 | Director · Chief Executive Officer | July 15, 2020 | July 17, 2020 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2029-08-08 | Direct | 0 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Disposition to issuer · Disposed 3,033 · Balance 0 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-08-08 | Direct | 3,033 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Grant · Acquired 3,033 · Balance 3,033 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.40 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2026-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-11 · Disposition to issuer · Disposed 1,519 · Balance 0 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-11-25 | Direct | 1,519 |
Reported balance
After 2026-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-11 · Grant · Acquired 1,519 · Balance 1,519 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2030-07-27 | Direct | 0 |
Reported balance
After 2026-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-11 · Disposition to issuer · Disposed 12,136 · Balance 0 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2030-07-27 | Direct | 12,136 |
Reported balance
After 2026-02-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-11 · Grant · Acquired 12,136 · Balance 12,136 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 300,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 300,000 · Balance 300,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
Travere Therapeutics, Inc.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,500 |
Ending reported balance
After 2026-09-10 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-10 · Exercise / conversion · Acquired 10,000 · Balance 101,500 Row 2 · 2026-09-10 · Exercise / conversion · Acquired 10,000 · Balance 111,500 Row 3 · 2026-09-10 · Sale · Disposed 1,700 · Balance 109,800 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F2: The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-09-10 · Sale · Disposed 1,200 · Balance 108,600 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F3: The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-10 · Sale · Disposed 14,000 · Balance 94,600 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F4: The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 6 · 2026-09-10 · Sale · Disposed 3,100 · Balance 91,500 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F5: The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-10 · Exercise / conversion · Disposed 10,000 · Balance 0 F6: The stock option is fully vested and exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.52 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-10 · Exercise / conversion · Disposed 10,000 · Balance 0 F6: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.
F2: The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2022 Filed May 13, 2022 00:26 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001209191-22-028697 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-05-10 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:26 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028697 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001493152-22-002554 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 26, 2023 and thereafter the remaining shares vest and become exercisable in equal quarterly installments over the following 24 months. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 14:16 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon Stock | 11,187 | $5.82 | $65,108.34 |
DisclosureSEC source: 0001493152-21-029297 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,647 Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:22 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon Stock | 12,000 | $7.00 | $84,000.00 |
DisclosureSEC source: 0001493152-21-022936 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,460 Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 21:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001493152-21-018910 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2031-08-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on August 4, 2022 and thereafter the remaining shares vest and become exercisable in equal quarterly installments over the following 24 months. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:19 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-21-033849 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-05-13 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:19 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033849 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:38 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001213900-20-017812 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Ordinary Shares · 300,000 shares Expires 2027-07-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030748 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030748 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Read SEC document |
| August 28, 2019 Filed Aug 29, 2019 20:16 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | PurchaseOrdinary Shares | 20,000 | $0.68 | $13,620.00 |
DisclosureSEC source: 0001213900-19-016939 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,761 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 20:18 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | PurchaseOrdinary Shares | 100,000 | $0.46 | $45,700.00 |
DisclosureSEC source: 0001213900-19-016791 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,761 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:37 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029156 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:37 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029156 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 21:27 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001213900-19-005894 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Ordinary Shares · 125,000 shares Expires 2026-04-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on April 4, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through April 4, 2022. Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:06 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001209191-18-029720 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:06 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029720 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:19 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033722 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:19 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033722 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.